References - Neonatal Intensive Care Drug Manual

|
Neonatal Intensive Care Drug Manual
|
bet | 389/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
References
|
Part 12: Pediatric Advanced Life Support: Web-based Integrated 2010 & 2015 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. https://eccguidelines.heart.org/index.php/circulation/cpr-ecc-guidelines-2/part-12-pediatric-advanced-life-support/?strue=1&id=3-6-6-1. 2015.
Truhlar A, Deakin CD, Soar J, Khalifa GE, Alfonzo A, Bierens JJ, Brattebo G, Brugger H, Dunning J, Hunyadi-Anticevic S, Koster RW, Lockey DJ, Lott C, Paal P, Perkins GD, Sandroni C, Thies KC, Zideman DA, Nolan JP, Cardiac arrest in special circumstances section C. European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances. Resuscitation. 2015;95:148-201.
Moe-Byrne T, Brown JV, McGuire W. Naloxone for opiate-exposed newborn infants. Cochrane Database Syst Rev. 2013:CD003483.
Elmekkawi A, Abdelgadir D, Van Dyk J, Choudhury J, Dunn M. Use of naloxone to minimize extubation failure after premedication for INSURE procedure in preterm neonates. Journal of Neonatal-Perinatal Medicine. 2016;9:363-70
Wiener PC, Hogg MI, Rosen M. Effects of naloxone on pethidine-induced neonatal depression. Part II--Intramuscular naloxone. Br Med J. 1977;2:229-31.
Van Der Lee R, Ceelie I, Tibboel D, De Wildt SN. Muscle rigidity and respiratory compromise in a term neonate during morphine infusion; serious adverse event determined by using the naranjo algorithm. Clinical Pharmacology and Therapeutics. 2009;1):S69-S70.
Barr PA. Hypoxaemia during mechanical ventilation for severe hyaline membrane disease following sedation with morphine sulphate. Australian Paediatric Journal. 1981;17:296-7.
Darnell CM, Thompson J, Stromberg D, Roy L, Sheeran P. Effect of low-dose naloxone infusion on fentanyl requirements in critically ill children. Pediatrics. 2008;121:e1363-71.
Tofil NM, Benner KW, Faro SJ, Winkler MK. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Pediatr Crit Care Med. 2006;7:252-4.
Moreland TA, Brice JE, Walker CH, Parija AC. Naloxone pharmacokinetics in the newborn. Br J Clin Pharmacol. 1980;9:609-12.
Bonta BW, Gagliardi JV, Williams V, Warshaw JB. Naloxone reversal of mild neurobehavioral depression in normal newborn infants after routine obstetric analgesia. Journal of Pediatrics. 1979;94:102-5.
Australian Injectable Drugs Handbook, 7th Edition. Accessed 29/08/2018: https://aidh.hcn.com.au/
MIMSOnline. Accessed 29/08/2018: https://www.mimsonline.com.au.acs.hcn.com.au/
Fischer CG, Cook DR. The respiratory and narcotic antagonistic effects of naloxone
Gerhardt T, Bancalari E, Cohen H, Rocha LF. Use of naloxone to reverse narcotic respiratory depression in the newborn infant. The Journal of pediatrics. 1977 Jun 1;90(6):1009-12.
Beilin B, Vatashsky E, Aronson HB, Weinstock M. Naloxone reversal of postoperative apnea in a premature infant. Anesthesiology: The Journal of the American Society of Anesthesiologists. 1985 Sep 1;63(3):317-8.
Gibbs J, Newson T, Williams J, Davidson DC. Naloxone hazard in infant of opioid abuser. The Lancet. 1989 Jul 15;334(8655):159-60.
Deshpande G, Gill A. Cardiac arrest following naloxone in an extremely preterm neonate. European journal of pediatrics. 2009 Jan 1;168(1):115.
|
|
|
| |